✨ Free AI Report
GB Sciences Inc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research GB Sciences Inc
Company Research

GB Sciences Inc: Business Overview, Financials & Competitive Analysis

GB Sciences Inc scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage plant-inspired biopharmaceutical with niche focus but limited scale and regulatory clarity. GB Sciences operates in an emerging plant-based therapeutics space with regulatory pathways still developing. The company has demonstrated proof-of-concept in Parkinson's disease and COVID-related hyperinflammation; however, as a small-cap OTC-traded company with limited revenue and employee base.

What is GB Sciences Inc's industry? GB Sciences Inc (gbsciences.com) operates in Pharmaceuticals. AskCyborg classifies GB Sciences Inc under Pharmaceuticals in its company registry.

GB Sciences Inc is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription ...

4/ 10Mixed

Cyborg Score thesis

Early-stage plant-inspired biopharmaceutical with niche focus but limited scale and regulatory...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
3 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest GB Sciences Inc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for GB Sciences Inc

AskCyborg analysts argue the bull and bear cases for GB Sciences Inc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
GB Sciences Inc OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

GB Sciences Inc Overview

Pro stress-test →

GB Sciences Inc is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market. The company operates as a vertically integrated cannabis company in Las Vegas, focused on cultivation and biopharmaceutical research and development.

Strategic Profile

Pro stress-test →

The company's goal is to create patented formulations of plant-inspired, minimum essential mixtures for use as prescription medications. GB Sciences' novel Parkinson's disease medication has been featured in major media outlets, with the company discussing cannabinoid-based treatments for neurodegenerative disorders.

Competitive Landscape

Pro stress-test →

GB Sciences competes indirectly with traditional biopharmaceutical companies developing Parkinson's therapies (e.g., Eli Lilly, Biogen) and cannabis-focused biotech firms exploring cannabinoid therapeutics (e.g., Zynerba Pharmaceuticals, GW Pharmaceuticals/Jazz Pharmaceuticals). The company's plant-inspired approach differentiates it from synthetic small-molecule developers, but the nascent regulatory environment for cannabis-derived pharmaceuticals limits direct comparables.

Industry Context

GB Sciences Inc operates in Pharmaceuticals.

Key facts

Headquarters: Las Vegas, Nevada · Employees: 19 · Revenue: $23M · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for GB Sciences Inc.

  • Focused pipeline: GB Sciences concentrates on two primary therapeutic areas—Parkinson's disease (with completed dose-response studies) and hyperinflammatory conditions, enabling targeted R&D spend
  • Plant-based differentiation: The company's proprietary approach to cannabis and plant-derived therapeutics targets an underexplored therapeutic class with less developer competition than traditional small-molecule pharma
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2023Featured on Worldwide Business with Kathy Ireland to discuss plant-inspired medicines and dose-response study results for Parkinson's disease medication
  • 2021Achieved positive proof-of-concept results for therapies designed to suppress COVID-related hyperinflammation
Get alerted when GB Sciences Inc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Compare GB Sciences Inc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

GB Sciences Inc operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about GB Sciences Inc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare GB Sciences Inc and its top competitor on Cyborg Score”
“What did GB Sciences Inc do this quarter?”
“Is GB Sciences Inc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does GB Sciences Inc do?+
GB Sciences Inc is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription ...
What is GB Sciences Inc's Cyborg Score?+
GB Sciences Inc has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are GB Sciences Inc's main competitors?+
Named competitors include Parkinson's disease therapeutics, Neurodegeneration therapies, Cannabinoid-based therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full GB Sciences Inc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the GB Sciences Inc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track GB Sciences Inc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual